Mepolizumab in adolescents with severe eosinophilic asthma not eligible for omalizumab: one center’s early clinical experience

Click to increase image sizeClick to decrease image size

Acknowledgements

We would like to thank Sister Phillipa Madge, Paediatric Asthma Nurse Specialist who assessed our patients during mepolizumab treatment and our Respiratory Physiology team who monitored lung function.

Declaration of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.